Most recently, pharmaceutical companies have developed anti‐diabetic treatment through anti‐obesity approaches like GLP‐1R agonists [34] or co‐agonists for glucose‐dependent insulinotropic polypeptide receptor (GIPR) and GLP‐1R [35]. This evidence concerns the gene GIPR and obesity disorder.